CRISPR Therapeutics reports $91.2 million second quarter net loss
CRISPR Therapeutics (CRSP) reported Q2 2026 total revenue of $10.2M and a net loss of $91.2M for the quarter ended June 30. Cash, cash equivalents and marketable securities were $2.36B vs $1.98B at end-2025. CASGEVY revenue was $76M, up 78% QoQ and 151% YoY. The company cited FDA approval for children as young as 2 and began Phase 1 trials for CTX340 and CTX460.
How this was made
The 30-second read
Why it matters
Traders can use the disclosed revenue, net loss, expense levels, and cash balance to update near-term valuation and runway assumptions, while the pediatric approval and new Phase 1 trials add incremental catalyst optionality.
Market read
A results-and-catalyst update for CRSP, combining a large quarterly net loss with strong CASGEVY revenue growth and additional regulatory/pipeline milestones.
What to watch
Cash and marketable securities rose to $2.36B from $1.98B at end-2025, which may extend runway and reduce immediate dilution pressure.
Background
Quiver FilingTracker summarizes CRISPR Therapeutics’ Q2 2026 financials and highlights CASGEVY commercialization and early pipeline activity.
Ticker impact
CRISPR Therapeutics reported Q2 2026 revenue of $10.2M and a net loss of $91.2M, alongside CASGEVY revenue growth to $76M.
Likely downside bias or elevated volatility until investors see clearer path to profitability and sustained CASGEVY scaling.
The article discloses hard financial results (revenue, net loss, expense lines) plus incremental regulatory/clinical milestones (pediatric approval, new Phase 1 starts), which can move sentiment, but the large net loss keeps the balance of news negative.
Market effects
Biotech investors may recalibrate expectations for gene-editing commercialization timelines and cash-burn tolerance after another large-loss quarter.
Limited direct regional spillover; primarily affects US-listed biotech sentiment.
CASGEVY pediatric approval and multi-country footprint can influence global gene-therapy commercialization narratives.
Counterpoint
Despite the large net loss, CASGEVY revenue growth (up 78% QoQ and 151% YoY) and pediatric expansion could indicate accelerating adoption that eventually offsets burn.
Key entities
- companyCRISPR Therapeutics
Subject of the article; reported Q2 2026 revenue, net loss, cash balance, CASGEVY revenue, and pipeline updates.
- productCASGEVY
CRISPR’s therapy; generated $76M in Q2 revenue and received FDA approval for children as young as 2.
- pipeline_programsCTX340 and CTX460
Phase 1 trials initiated per the article.
